title: Anticoagulant antidotes start yielding Phase III promise.
authors.forename: Dan
authors.initials: D
authors.lastname: Jones
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000925:Anticoagulants / Q000008:administration & dosage*; D000931:Antidotes / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic / Q000639:trends*; D006801:Humans
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000931:Antidotes; C000594745:idarucizumab